国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
16期
2449-2451
,共3页
局部亚低温%脑梗死%神经保护
跼部亞低溫%腦梗死%神經保護
국부아저온%뇌경사%신경보호
Local mild hypothermia%Cerebral infarction%Neuroprotection
目的 观察脑局部亚低温治疗在脑梗死急性期的疗效,并评估其应用的安全性.方法 40例急性脑梗死患者随机分为A、B两组,A组在常规治疗的基础上给予脑局部亚低温治疗72小时,疗程为14天.两组在治疗开始、结束时分别行临床神经功能缺损(NIHSS)评分和日常生活活动能力量表(BI)评分,同时观察生命体征、内环境各项指标变化及并发症的发生情况.结果 治疗结束时A组NIHSS、BI评分明显优于B组(P<0.05),各项指标及并发症无统计学差异.结论 脑局部亚低温治疗对改善急性期脑梗死患者的神经功能缺损具有积极意义,疗效确切,不良反应较少,可作为目前基层医院的治疗选择.
目的 觀察腦跼部亞低溫治療在腦梗死急性期的療效,併評估其應用的安全性.方法 40例急性腦梗死患者隨機分為A、B兩組,A組在常規治療的基礎上給予腦跼部亞低溫治療72小時,療程為14天.兩組在治療開始、結束時分彆行臨床神經功能缺損(NIHSS)評分和日常生活活動能力量錶(BI)評分,同時觀察生命體徵、內環境各項指標變化及併髮癥的髮生情況.結果 治療結束時A組NIHSS、BI評分明顯優于B組(P<0.05),各項指標及併髮癥無統計學差異.結論 腦跼部亞低溫治療對改善急性期腦梗死患者的神經功能缺損具有積極意義,療效確切,不良反應較少,可作為目前基層醫院的治療選擇.
목적 관찰뇌국부아저온치료재뇌경사급성기적료효,병평고기응용적안전성.방법 40례급성뇌경사환자수궤분위A、B량조,A조재상규치료적기출상급여뇌국부아저온치료72소시,료정위14천.량조재치료개시、결속시분별행림상신경공능결손(NIHSS)평분화일상생활활동능역량표(BI)평분,동시관찰생명체정、내배경각항지표변화급병발증적발생정황.결과 치료결속시A조NIHSS、BI평분명현우우B조(P<0.05),각항지표급병발증무통계학차이.결론 뇌국부아저온치료대개선급성기뇌경사환자적신경공능결손구유적겁의의,료효학절,불량반응교소,가작위목전기층의원적치료선택.
Objective To evaluate the clinical efficacy of brain mild hypothermia treatment in the patients with acute cerebral infarctions,and evaluate the safety of its application.Methods 40 cases of acute cerebral infarction were randomly divided into group A and B,on the basis of routine treatment,group A was treated with local mild hypothermia treatment in 72 hours,14 days for a course.At the beginning and the end of treatment two groups were all evaluted respectively with clinical neurological function deficit scale (NIHSS) and activities of daily living scale (BI) score,simultaneous observation of vital signs,environmental indicators change and complications were also observed.Results At the end of treatment,NIHSS and the BI score in group A were significantly lower than those in group B (P<0.05),no significant difference of each index and complications was found.Conclusion Local brain mild hypothermia treatment has positive curative effect in improving neurological function in acute cerebral infarction patients,with less adverse reaction,which can be used as the treatment of choice for primary hospitals.